Malaysian AIDS Council confirms MOH-backed outreach session in Kota Bharu as Kelantan cops chastised over ‘gay sex party' accusation
After Kelantan police claimed that the raid was against an alleged 'gay sex party', MAC said the session was in collaboration with Kota Jembal Health Clinic and part of a strategic approach introduced by the Health Ministry.
'We strongly urge that programmes such as this not be misrepresented or unnecessarily politicised, as such actions may disrupt collective efforts to tackle HIV in Malaysia.
'Instead, community-based approaches like DHSKP should receive broad support as a proven and effective strategy to end AIDS by 2030,' it said in a statement.
MAC said the session was held from 8pm to 2am and had reached over 70 high-risk individuals, with services scheduled outside office hours to improve accessibility.
It had included information on HIV transmission risks, prevention, and the benefits of antiretroviral (ARV) treatment under the Undetectable = Untransmittable (U=U) principle.
Participants underwent confidential Community-Based Testing for HIV, with each screening taking 10 to 15 minutes, followed by counselling for those with reactive results.
Brief counselling was provided by medical officers and clients were referred to the clinic for further follow-up.
'DHSKP emphasises tailored service delivery that meets the specific needs of target populations, free from stigma, and carried out through collaboration between public healthcare facilities and community organisations.
'It covers screening, counselling, treatment, and support, and aims to close the gap in access to healthcare while improving the effectiveness of HIV prevention and treatment,' it said.
This comes as a coalition of civil society groups had also urged Kelantan police to revise their statement on a June 2025 raid of an alleged 'gay sex party' here, which they clarified was in fact a health outreach event.
The groups, led by transgender rights advocacy group Justice for Sisters, said media reports following the raid resulted in harmful and stigmatising remarks that have intensified fear among lesbian, gay, bisexual, transgender, and queer (LGBTQ) individuals seeking health services.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New Straits Times
2 hours ago
- New Straits Times
Price labelling rule stays: MoH prioritises education over penalties
PUTRAJAYA: The Health Ministry (MoH) will continue focusing on education and awareness in enforcing the Price Control and Anti-Profiteering (Medicine Price Labelling) Order 2025, despite a pending judicial review application challenging the regulation. Health Minister Datuk Seri Dr Dzulkefly Ahmad said the ministry respected the legal process but was committed to ensuring smooth implementation of the order through educational enforcement. "We will continue with this approach to avoid enforcement gaps while the court process is ongoing," he told reporters after officiating the 2025 National Health Technology Assessment Conference and the 30th anniversary of the Malaysian Health Technology Assessment Section (MaHTAS) here today. The regulation, which came into force on May 1, mandates all private clinics and community pharmacies to display medicine prices on shelves, in catalogues or on written price lists, under the Price Control and Anti-Profiteering (Medicine Price Labelling) Order 2025. Dzulkefly was responding to reports that the Malaysian Medical Association (MMA) and seven other organisations have applied for leave to initiate a judicial review of the order. Among the applicants are the Sabah Private Practitioners Association (APPS), the Malaysian Association for the Advancement of Functional and Interdisciplinary Medicine (MAAFIM), the Malaysian Muslim Doctors Association (PERDIM), and the Federation of Private Medical Practitioners' Associations Malaysia (FPMPAM). On May 4, Dzulkefly had clarified that no fines or compounds would be issued during the first three months of enforcement, as the ministry's priority was on stakeholder education. As of now, neither MoH nor the Domestic Trade and Cost of Living Ministry has announced an extension to the grace period, which ends tomorrow (July 31). – BERNAMA
New Straits Times
2 hours ago
- New Straits Times
MoH open to reclassifying etomidate under Dangerous Drugs Act
PUTRAJAYA: The Health Ministry (MoH) is open to reviewing the proposal to list 'etomidate' under the Dangerous Drugs Act 1952 following reports of its frequent abuse, its minister Datuk Seri Dr Dzulkefly Ahmad said. He said that based on current clinical practices, the MoH was always ready to carry out evaluations or studies based on evidence presented by any party. Etomidate is currently listed under the Poisons Act 1952. "Any proposal can be considered, but at the end of the day, I look at the evidence base when evaluating something," he told a press conference after officiating the 2025 National Health Technology Assessment Conference and the 30th Anniversary Celebration of the Health Technology Assessment Section (MaHTAS) here today. Bandar Kuching MP Dr Kelvin Yii had before this urged the government to list etomidate under both the Poisons Act 1952 and the Dangerous Drugs Act 1952, citing reports of its fatal effects in Singapore. He said etomidate was an intravenous anaesthetic that had been misused as a recreational substance through vape products, often marketed as 'Kpods'. Kpods is a street term that usually refers to vape pods laced or contaminated with harmful chemicals or synthetic drugs, rather than just regular vape liquids like nicotine or flavouring. In a related development, Dzulkefly said the government is currently reviewing a proposal to ban e-cigarettes or vapes in the country. "I'm taking note, but I don't want to act hastily. We are taking this very seriously, and it needs to go through a thorough evaluation and consideration of legal and public health impacts," he said. – BERNAMA
The Sun
4 hours ago
- The Sun
Shenzhen and Hong Kong Join Hands to Promote the Development of the Hetao Shenzhen-Hong Kong Science & Technology Innovation Co-operation Zone
HONG KONG SAR - Media OutReach Newswire - 30 July 2025 - The Greater Bay Area International Clinical Trial Institute of Hong Kong ('GBAICTI'), the Greater Bay Area International Clinical Trials Center of Shenzhen ('BAY TRIAL'), Immuno Cure BioTech ('Immuno Cure') in Hong Kong are pleased to jointly announce today the signing of a tripartite Memorandum of Understanding ('MOU') in Shenzhen on July 29, 2025. This collaboration aims to advance the globalization of clinical trials in the Guangdong-Hong Kong-Macau Greater Bay Area ('GBA'), further deepens clinical research cooperation between Hong Kong and Shenzhen, and implements the first ever cross-border multi-centre Phase II clinical trial project for ICVAX, a therapeutic DNA vaccine for HIV/AIDS, developed through collaboration between Immuno Cure and the AIDS Institute at the University of Hong Kong. This marks a significant milestone in the development of the Hetao Shenzhen-Hong Kong Science and Technology Innovation Co-operation Zone. This collaboration is witnessed by a Hong Kong Government delegation led by the Director of Health, Dr. Ronald LAM, and a Shenzhen Government delegation led by the Deputy Director General of Public Hygiene and Health Commission of Shenzhen Municipality, Ms. ZHOU Liping, following their GBA Clinical Trial Collaboration meeting held in Shenzhen. GBAICTI and the BAY TRIAL plan to establish the GBA Clinical Trial Collaboration Platform ('Platform') by the end of this year. The Platform is expected to offer a range of services, including project evaluation, trial design consultation, and subject recruitment planning for multi-centre clinical trials, provided by a joint Shenzhen-Hong Kong advisory team; integration of artificial intelligence technologies to assist with matching clinical trial institutions and researchers, as well as offering intelligent consultation services; establishment of a coordinated ethics review mechanism between the two regions to enhance approval efficiency; promotion of talent exchange, collaboration, and professional training; creation of a research talent pool to facilitate talent mobility and regional collaboration; and as a pilot, the development of clinical databases and biobanks based on disease areas of strength in both Shenzhen and Hong Kong. Professor Bernard CHEUNG Man-yung, Chief Executive Officer of GBAICTI, said: 'The ICVAX vaccine, developed by Immuno Cure and the AIDS Institute at the University of Hong Kong, is now poised for cross-border clinical trials in the Greater Bay Area. This highlights the achievements and potential of innovation and technology in China and the Hong Kong SAR. If the clinical trial results are positive, the new vaccine would bring hope to HIV/AIDS patients worldwide, particularly in Belt and Road countries. We aim to leverage the strength of both Guangdong and Hong Kong to establish the Guangdong-Hong Kong-Macao Greater Bay Area as a global hub for clinical trials.' Dr. LI Yichong, Director of BAY TRIAL, said: 'This collaboration marks the first cross border clinical trial project between the BAY TRIAL and Hong Kong, signifying a new phase in the cooperation between Shenzhen and Hong Kong in the biopharmaceutical sector of GBA. We will fully leverage the synergistic advantages of both regions to establish an international clinical trial platform with the BAY TRIAL, continuously injecting new momentum into the high-quality development of the Bay Area's pharmaceutical and medical device industry.' Since the first discovery of AIDS in 1981, 40 million people have died from HIV infection. Currently, there are still over 39 million people living with HIV worldwide. Although antiretroviral therapy ('ART') can effectively control HIV, it cannot cure the disease, highlighting the importance of immunotherapy. Immunotherapy aims to enhance the host's immune response, with the expectation of controlling viral replication without ART, ultimately achieving complete viral suppression and functional cure. Immuno Cure's ICVAX induces broad-spectrum, multifunctional virus-specific T cells to achieve the goal of controlling viral replication without ART. Immuno Cure completed the first-in-human Phase I clinical trial of the ICVAX vaccine in November 2024. The results demonstrated excellent safety and good immunogenicity. This year, two multi-center Phase II clinical trials will be conducted to evaluate the mechanism of action and efficacy, respectively, of ICVAX in humans. Both are randomized, double-blind, placebo-controlled, dose-escalation studies, with clinical trial centres in the Prince of Wales Hospital in Hong Kong and eight Grade 3A hospitals in China, including The Third People's Hospital of Shenzhen, Beijing Ditan Hospital, Beijing Youan Hospital, Guangzhou Eighth People's Hospital, Tianjin Second People's Hospital, The Sixth People's Hospital of Zhengzhou, Chengdu Public Health Clinical Medical Center, and Chongqing Public Health Medical Center. Dr. Xia JIN, Chief Executive Officer of Immuno Cure, said: 'We are delighted to receive support from both GBAICTI and BAY TRIAL, integrating medical resources from both regions to advance Immuno Cure's therapeutic vaccine for HIV, ICVAX, to multi-center Phase II clinical trials. We will continue to collaborate with the HKU AIDS Institute to drive innovation in drug development, leverage local advantages in drug research and translation, accelerate ICVAX towards commercialization, provide more effective treatment options for HIV patients, and contribute to global health.' GBAICTI, BAY TRIAL, and Immuno Cure look forward to further deepening clinical trial cooperation between Shenzhen and Hong Kong in future collaborations, jointly promoting the development and globalisation of innovative drug development, and supporting the national 'Healthy China' strategic goals.
